Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2014

Open Access 01-12-2014 | Research

Prognostic value of miR-96 in patients with acute myeloid leukemia

Authors: Jiangning Zhao, Quanyi Lu, Junfeng Zhu, Jianguo Fu, Yun-xian Chen

Published in: Diagnostic Pathology | Issue 1/2014

Login to get access

Abstract

Objective

Aberrant expression of miRNA (miR)-96 is associated with tumorigenesis and tumor progression in several solid cancers. However, little is known about the expression and prognostic value of miR-96 in acute myeloid leukemia (AML). Therefore, the aim of this study was to investigate the correlation of miR-96 expression with clinicopathological features and prognosis of AML.

Methods

Real-time quantitative RT-PCR assay was performed to evaluate the expression levels of miR-96 in mononuclear cells from bone marrow or peripheral blood specimens in 86 patients with newly diagnosed AML.

Results

Compared with normal controls, miR-96 expression was significantly downregulated in patients with newly diagnosed AML (P < 0.001). In analysis of 14 diagnosis/CR-paired samples, the expression level of miR-96 was found markedly elevated in patients after treatment than before (P < 0.001). Moreover, lower levels of miR-96 were associated with a higher white blood cell count, bone marrow blast count (P < 0.001 and 0.022, respectively), and lower hemoglobin and platelet count (P = 0.036 and 0.033, respectively). Although the low-expression group seemed to have a lower CR rate (53.85% vs 70.0%), there was no significant difference between the two groups (P = 0.213). The low-expression group had a lower relapse-free survival (RFS) (P = 0.038) and overall survival (OS) (P = 0.022) compared with the high-expression group during a median follow-up of 20 months.

Conclusion

Our data demonstrated that the expression of miR-96 was downregulated in newly diagnosed AML patients and associated with leukemic burden, as well as RFS and OS. This suggests that miR-96 detection might become a potential biomarker of prognosis and monitoring in AML.

Virtual slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1434808553949498​
Appendix
Available only for authorised users
Literature
1.
Tallman MS, Gilliland DG, Rowe JM: Drug therapy for acute myeloid leukemia. Blood. 2005, 106: 1154-1163. 10.1182/blood-2005-01-0178.PubMedCrossRef
2.
Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornbalu SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce CM: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008, 111: 3183-3189. 10.1182/blood-2007-07-098749.PubMedPubMedCentralCrossRef
3.
Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B: MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008, 111: 5078-5085. 10.1182/blood-2008-01-133355.PubMedCrossRef
4.
Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T, Andrew Lister T, Young BD, Debernardi S: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One. 2008, 3: e2141-10.1371/journal.pone.0002141.PubMedPubMedCentralCrossRef
5.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116: 281-297. 10.1016/S0092-8674(04)00045-5.PubMedCrossRef
6.
Chen T: The role of MicroRNA in chemical carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2010, 28: 89-124. 10.1080/10590501.2010.481477.PubMedCrossRef
7.
Ufkin ML, Peterson S, Yang X, Driscoll H, Duarte C, Sathyanarayana P: miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res. 2014, 38: 402-410. 10.1016/j.leukres.2013.12.021.PubMedPubMedCentralCrossRef
8.
Wang XS, Gong JN, Yu J, Wang F, Zhang XH, Yin XL, Tan ZQ, Luo ZM, Yang GH, Shen C, Zhang JW: MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia. Blood. 2012, 119: 4992-5004. 10.1182/blood-2011-10-385716.PubMedCrossRef
9.
Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, Huang X, Wang L: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 2012, 180: 2440-2451. 10.1016/j.ajpath.2012.02.023.PubMedCrossRef
10.
He T, Qi F, Jia L, Wang S, Song N, Guo L, Fu Y, Luo Y: MicroRNA-542-3p inhibits tumor angiogenesis by targeting Angiopoietin2. J Pathol. 2014, [Epub ahead of print]
11.
Wang W, Li F, Zhang Y, Tu Y, Yang Q, Gao X: Reduced expression of miR-22 in gastric cancer is related to clinicopathologic characteristics or patient prognosis. Diagn Pathol. 2013, 8: 102-10.1186/1746-1596-8-102.PubMedPubMedCentralCrossRef
12.
Marcucci G, Maharry K, Radmacher MD, Mrozek K, Vukosavljevic T, Paschka P, Whitman SP, Langer C, Baldus CD, Liu CG, Ruppert AS, Powell BL, Carroll AJ, Caliqiuri MA, Kolitz JE, Larson RA, Bloomfield CD: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a cancer and leukemia group B study. J Clin Oncol. 2008, 26: 5078-5087. 10.1200/JCO.2008.17.5554.PubMedPubMedCentralCrossRef
13.
Li G, Zhang Z, Tu Y, Jin T, Liang H, Cui G, He S, Gao G: Correlation of microRNA-372 upregulation with poor prognosis in human glioma. Diagn Pathol. 2013, 8: 1-10.1186/1746-1596-8-1.PubMedPubMedCentralCrossRef
14.
Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller K, Lein M, Kristiansen G, Jung K: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010, 126: 1166-1176.PubMed
15.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature. 2005, 435: 834-838. 10.1038/nature03702.PubMedCrossRef
16.
Haflidadóttir BS, Larne O, Martin M, Persson M, Edsjö A, Bjartell A, Ceder Y: Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1. PLoS One. 2013, 8: e72400-10.1371/journal.pone.0072400.PubMedPubMedCentralCrossRef
17.
Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, Yoshino H, Kawahara K, Nishiyama K, Seki N, Nakagawa M: MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011, 102: 522-529. 10.1111/j.1349-7006.2010.01816.x.PubMedCrossRef
18.
Wang Y, Luo H, Li Y, Chen T, Wu S: Yang L: hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. Mol Med Rep. 2012, 5: 260-265.PubMed
19.
Xu D, He X, Chang Y, Xu C, Jiang X, Sun S, Lin J: Inhibition of miR-96 expression reduces cell proliferation and clonogenicity of HepG2 hepatoma cells. Oncol Rep. 2013, 29: 653-661.PubMed
20.
Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X, Song L: Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 2010, 5: e15797-10.1371/journal.pone.0015797.PubMedPubMedCentralCrossRef
21.
Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD: Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003, 21: 4642-4649. 10.1200/JCO.2003.04.036.PubMedCrossRef
22.
Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.PubMedCrossRef
23.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.PubMedCrossRef
24.
De Mello MR1, Albuquerque DM, Pereira-Cunha FG, Albanez KB, Pagnano KB, Costa FF, Metze K, Lorand-Metze I: Molecular characteristics and chromatin texture features in acute promyelocytic leukemia. Diagn Pathol. 2012, 7: 75-10.1186/1746-1596-7-75.PubMedPubMedCentralCrossRef
25.
Masetti R, Togni M, Astolfi A, Pigazzi M, Manara E, Indio V, Rizzari C, Rutella S, Basso G, Pession A, Locatelli F: DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia. Oncotarget. 2013, 4: 1712-1720.PubMedPubMedCentralCrossRef
26.
Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, Casadio R, Pession A, Basso G, Locatelli F: CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013, 121: 3469-3472. 10.1182/blood-2012-11-469825.PubMedCrossRef
27.
Kralik JM1, Kranewitter W, Boesmueller H, Marschon R, Tschurtschenthaler G, Rumpold H, Wiesinger K, Erdel M, Petzer AL, Webersinke G: Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia. Diagn Pathol. 2011, 6: 19-10.1186/1746-1596-6-19.PubMedPubMedCentralCrossRef
28.
Sánchez‒Espiridión B, Martín‒Moreno AM, Montalbán C, Figueroa V, Vega F, Younes A, Medeiros LJ, Alvés FJ, Canales M, Estévez M: MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. Br J Haematol. 2013, 162: 336-347. 10.1111/bjh.12390.CrossRef
29.
Mihelich BL, Khramtsova EA, Arva N, Vaishnav A, Johnson DN, Giangreco AA, Martens-Uzunova E, Bagasra O, Kajdacsy-Balla A, Nonn L: miR-183-96-182 cluster is overexpressed in prostate tissue and regulates zinc homeostasis in prostate cells. J Biol Chem. 2011, 286: 44503-44511. 10.1074/jbc.M111.262915.PubMedPubMedCentralCrossRef
30.
Tang H, Bian Y, Tu C, Wang Z, Yu Z, Liu Q, Xu G, Wu M, Li G: The miR-183/96/182 cluster regulates oxidative apoptosis and sensitizes cells to chemotherapy in gliomas. Curr Cancer Drug Targets. 2013, 13: 221-231. 10.2174/1568009611313020010.PubMedCrossRef
31.
Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, Sengupta S, Archer T, Remke M, Bai AH, Warren P, Pfister SM, Steen JA, Pomeroy SL, Cho YJ: Pleiotropic effects of miR-183 96 182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012, 123: 539-552. 10.1007/s00401-012-0969-5.PubMedCrossRef
32.
Chen RX, Xia YH, Xue TC, Ye SL: Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells. Mol Med Rep. 2012, 5: 800-804.PubMed
33.
Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, Liu J, Yu J, Chen J: miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res. 2010, 70: 6015-6025. 10.1158/0008-5472.CAN-09-4531.PubMedCrossRef
34.
Vishwamitra D, Li Y, Wilson D, Manshouri R, Curry CV, Shi B, Tang XM, Sheehan AM, Wistuba II, Shi P, Amin HM: MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression. Am J Pathol. 2012, 180: 1772-1780.1. 10.1016/j.ajpath.2012.01.008.PubMedPubMedCentralCrossRef
Metadata
Title
Prognostic value of miR-96 in patients with acute myeloid leukemia
Authors
Jiangning Zhao
Quanyi Lu
Junfeng Zhu
Jianguo Fu
Yun-xian Chen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-9-76

Other articles of this Issue 1/2014

Diagnostic Pathology 1/2014 Go to the issue

Research

Overexpression of both platelet-derived growth factor-BB and vascular endothelial growth factor-C and its association with lymphangiogenesis in primary human non-small cell lung cancer

Research

p16INK4a expression in retinoblastoma: a marker of differentiation grade

Research

Association of TRPS1 gene with different EMT markers in ERα-positive and ERα-negative breast cancer

Case Report

Coexistent hairy cell leukaemia and hepatosplenic t-cell lymphoma: a case report

Research

Association of apolipoprotein A5 genetic polymorphisms with steroid-induced osteonecrosis of femoral head in a Chinese Han population

Review

Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review